About Nanopath

Nanopath is dedicated to improving health equity worldwide, starting with women’s health. Nanopath’s proprietary molecular diagnostic test takes a radically new approach to how clinicians measure and characterize human health. Through its novel biosensing technology, the company has the potential to enable fast, high-complexity tests to be performed in minutes and at the point-of-care, rather than in centralized laboratories. Nanopath’s founders seek to improve the lives of women and other underserved populations, while simultaneously enhancing the lives of the Nanopath team members through purpose-driven work that helps to develop and deploy its products. The company is headquartered in Cambridge, Mass., at LabCentral, the premier launchpad for high-potential life sciences and biotech start-ups. Nanopath was spun out of Dartmouth College in 2019 in partnership with Dartmouth Hitchcock Medical Center.